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ABSTRACT
Aims Because immunoglobulin abnormalities may affect
the kidney, investigation of renal biopsies requires
immunohistological study of light chains. A problem is
that most antibodies to light chains react with whole
immunoglobulins as well as free light chains, and there
are generally many more whole immunoglobulins than
free light chains. The usefulness of antibodies that only
detected free light chains was investigated.
Methods Antibodies to free light chains were used in
an immunoperoxidase method on parafﬁn sections of
198 renal biopsies, and compared with conventional
antibodies against light chains examined by
immunoﬂuorescence on 13 frozen sections and by
immunoperoxidase on 46 parafﬁn sections.
Results Immunoﬂuorescence and immunoperoxidase
were concordant on 10 of 13 biopsies.
Immunoﬂuorescence detected slight deposition of
light chains in three biopsies not shown by
immunoperoxidase, of undetermined clinical signiﬁcance.
Using immunoperoxidase, the free light chain antibodies
were more sensitive than conventional antibodies, giving
much cleaner staining and better detection of deposits in
AL amyloid, light chain deposition disease and
cryoglobulinaemic glomerulonephritis. The free light
chain antibodies showed discordance or ambiguity
between immunohistological and clinical ﬁndings in
seven (4%) of 185 patients with known immunoglobulin
status. These included two of 28 cases of AL amyloid
that showed no light chain deposition. The method was
not designed for detection of light chain restriction in
neoplastic plasma or lymphoplasmacytic cells.
Conclusions Polyclonal antibodies to free light chains
are an improvement on conventional antibodies in
immunoperoxidase study of parafﬁn sections of renal
biopsies and are useful in everyday practice.
INTRODUCTION
Abnormal immunoglobulin light chains may have
various effects on the kidney, especially cast nephro-
pathy, AL amyloidosis or deposition disease, although
they may have no detectable effects.1–4 Any study of
light chains in renal biopsies, by immunoﬂuorescence
on frozen or parafﬁn sections or immunoperoxidase
on parafﬁn sections, has disadvantages, including the
specially collected material required for frozen sec-
tions, impermanence of ﬂuorescence, and pretreat-
ment usually needed for parafﬁn sections, but most
antibodies give comparable ﬁndings between frozen
and parafﬁn sections.5–9
A problem is the speciﬁcity of antibodies against
light chains. Most polyclonal antibodies react with
light chains both free and bound to heavy chains, but
usually react preferentially with whole
immunoglobulins, because normal mean plasma con-
centrations of free light chains and whole immuno-
globulins are about 23 mg/L10 and 19 g/L,11 one
thousand times different. Monoclonal antibodies
may be speciﬁc for a free light chain, but the epitope
recognised may not be expressed or accessible in all
light chains.12
Polyclonal antibodies speciﬁc for free light chains
are available,10 with applications in measurement
of plasma light chains and diagnosis and manage-
ment of clinical immunoglobulin disorders.13 Our
study assessed the value of these antibodies in
immunohistology of parafﬁn sections of renal biop-
sies, including comparison with conventional
antibodies.
MATERIALS AND METHODS
Antibodies
Sheep antibodies to human free κ and λ light chains
were supplied by The Binding Site, Birmingham,
UK. Rabbit antibodies to κ and λ (A0191, A0193),
mouse antibody to serum amyloid A (M0759) and
ﬂuorescein-conjugated antibodies to κ and λ (F0198,
F0199) were obtained from Dako.
Immunostaining
For immunoperoxidase, endogenous peroxidase
was blocked on dewaxed 3 mm parafﬁn sections by
hydrogen peroxide. After preliminary experiments,
optimum antigen retrieval for sheep antibodies was
digestion with protease type 24 (Sigma, P8038),
0.05% w/v in phosphate buffered saline pH 7.2, at
37°C, initially for 45 min, with microscopic study
of completeness of digestion and further digestion
if necessary.5 Antibodies were applied at 1:400 (κ)
or 1:200 (λ) for 45 min, then rabbit anti-sheep
immunoglobulins, peroxidase-conjugated (Dako,
P0163), at 1:100, for 45 min, followed by diamino-
benzidine and hydrogen peroxide, and haematoxy-
lin. Various methods of antigen retrieval for rabbit
antibodies were tried, including no pretreatment,
protease digestion, trypsin digestion, microwave
heating, pressure cooking, and heating for 30 min
in antigen retrieval solution pH 9.0 provided in a
kit for an automated method (Bondmax: Leica
Microsystems, Milton Keynes, UK). Most pretreat-
ments matched automated antigen retrieval, but
protease abolished immunostaining and no pre-
treatment gave weak immunostaining. Antibodies
were applied at 1:20 000, followed by Bondmax
anti-rabbit Poly-HRP-IgG, peroxidase substrate and
counterstain. Amyloid A antibody (1:500) was used
without pretreatment followed by Bondmax anti-
mouse antibody. Frozen sections were covered with
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ﬂuoresceinated antibodies and examined by ﬂuorescence
microscopy.
Thirty-two patients were referred to the National
Amyloidosis Centre (NAC). Their renal biopsies were independ-
ently examined with the rabbit antibodies to light chains
without antigen retrieval, and with antibodies to amyloid A and
if necessary to other potential amyloid precursors.14
Renal biopsies
Thirteen biopsies examined by immunoﬂuorescence on frozen
sections were studied using the free light chain antibodies on
parafﬁn sections, as were another 185 parafﬁn-embedded biop-
sies. These included 46 biopsies used to compare the free light
chain and rabbit antibodies, 32 at NAC and 14 others.
Immunostained parafﬁn sections were examined without knowl-
edge of clinical features or original reports of light chain ﬁnd-
ings. Diagnoses were made in usual ways.15 Conventional
summary statistics (sensitivity, speciﬁcity and CIs of differences
in proportions) were calculated.
Evidence of immunoglobulin disorders
Apart from three cases studied by immunoﬂuorescence, all
others had evidence for or against a disorder of immunoglobu-
lins. Evidence was any of these: a serum paraprotein; a cryo-
globulin; an abnormal ratio of serum free κ to λ
concentrations10; or a monoclonal (Bence Jones) light chain in
urine. The Results mostly concentrate on the 185 biopsies,
selected because there was adequate information about immuno-
globulin status of the patients, 110 with an immunoglobulin
abnormality and 75 without. Free light chain immunostaining
was more likely to be done if an abnormality was known or sus-
pected or was in the differential diagnosis.
RESULTS
Comparison of immunoﬂuorescence and immunoperoxidase
Ten of 13 biopsies showed agreement between the methods,
with AL amyloid (5), no light chain deposition (3), and depos-
ition disease (2). The other three showed no free light chain
deposition, and only faint deposition on immunoﬂuorescence,
one of κ in tubular basement membranes with slight chronic
damage, one of κ in glomerular basement membranes but no
structural glomerular abnormality, and one of more λ than κ in
tubular basement membranes but no clinical immunoglobulin
abnormality.
Comparison of different antibodies using
immunoperoxidase
The 14 non-NAC biopsies comparing free light chain and rabbit
antibodies had cast nephropathy (3), amyloid (3, two AL, one
AA), no immunoglobulin abnormality (3), renal inﬁltration by
lymphoplasmacytic lymphoma or myeloma (2), cryoglobulinae-
mic glomerulonephritis (2, both type II) and deposition disease
(1). Rabbit antibodies after automated antigen retrieval showed
heavy staining of tubular epithelium, interstitial tissues and
blood, but background staining was much lighter without pre-
treatment (ﬁgures 1, 2). After automated antigen retrieval,
deposits of light chains in AL amyloid, cryoglobulinaemia and
deposition disease were impossible to distinguish from the back-
ground, and without pretreatment, immunostaining for light
chains was weak and only seen in one case, with AL amyloid.
Deposits were easily detected with free light chain antibodies,
with clean background and no blood in vessels (ﬁgures 3, 4).
Both types of antibody showed a preponderance of one light
chain in casts and tubular epithelium in cast nephropathy. Light
chain restriction was identiﬁed in the myelomatous inﬁltrate
only with rabbit antibodies, but with neither antibody in the
lymphoplasmacytic lymphoma. Comparison of the antibodies,
including ﬁndings in NAC (below), is in table 1.
Amyloid
With free light chain antibodies, 25 of 41 biopsies showed AL
amyloid (21 λ, four κ), with concordance between clinical and
Figure 2 The same renal biopsy as in ﬁgure 1. Immunostaining with
the rabbit antibody to κ light chains without pretreatment shows light
background staining but no detectable staining of amyloid deposits.
Figure 1 Renal biopsy containing amyloid in glomeruli in a patient
with a κ paraprotein. Immunostaining with the rabbit antibody to κ
light chains after automated antigen retrieval shows extensive staining
but no detectable selective staining of amyloid deposits.
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immunoperoxidase ﬁndings (tables 2, 3). NAC conﬁrmed λ AL
amyloid in 13 of 17 λ cases and κ AL amyloid in one of two κ
cases by immunohistology, and in four and one, respectively,
from overall evidence.
Eight biopsies showed AA amyloid and three nonAL, nonAA
amyloid with no free light chain immunostaining, concordant
with no immunoglobulin disorder. NAC conﬁrmed ﬁve cases of
AA amyloid by immunohistology, and identiﬁed two nonAL,
nonAA cases as LECT2 amyloid and one as ﬁbrinogen A α
amyloid. Another case had no clinical immunoglobulin
abnormality, but amyloid deposits reacted with antibodies to
amyloid A and free κ. NAC diagnosed AA amyloid
immunohistologically.
The other four cases had a clinical immunoglobulin abnor-
mality. One with a κ paraprotein showed deposition of both
free κ and amyloid A. NAC showed no deposition on immuno-
histology but considered this κ AL amyloid on overall evidence.
In the other three, no free light chain deposition was detected.
One with a λ Bence Jones protein was conﬁrmed λ AL amyloid
immunohistologically at NAC. One with a λ paraprotein had no
immunohistological deposition at NAC but was considered λ AL
amyloid on overall evidence. In one case with a κ paraprotein,
the amyloid reacted only with amyloid A antibody. AA amyloid
was conﬁrmed by NAC.
Other conditions
Light chain cast nephropathy
Findings were concordant between immunostaining for free
light chains and immunoglobulin abnormalities in 32 of 33
cases (26 κ, six λ), with deﬁnite preponderance of one light
chain in casts and tubular epithelial cells (ﬁgures 5, 6). In the
Table 1 Comparison of diagnostic accuracy of antibodies to free light chains
and conventional antibodies to light chains in 46 renal biopsies, compared with
final diagnosis of any renal abnormality related to light chain disorders, including
neoplastic infiltration
Antibodies to free light chains
Deposition No deposition
29 17
Abnormality/no abnormality Abnormality/no abnormality
28/1* 4†/13
Sensitivity 88%, specificity 93%
Conventional antibodies to light chains
Deposition No deposition
20 26
Abnormality/no abnormality Abnormality/no abnormality
20/0 12‡/14
Sensitivity 63%, specificity 100%
Difference in sensitivity (free light chain antibodies – conventional antibodies)=25%
(95% CI 9% to 41%); difference in specificity (free light chain antibodies –
conventional antibodies)=−7% (95% CI −14% to 0%).
*κ & AA deposition in AA amyloid.
†No deposition in AL amyloid (2), neoplastic infiltration (2).
‡No deposition in AL amyloid (8), cryoglobulinaemic glomerulonephritis (2), light
chain deposition disease (1), neoplastic infiltration (1).
Table 2 Light chain immunohistological findings in 41 renal biopsies containing
amyloid
AL amyloid
AA
amyloid
Other
amyloid
Final diagnosis 28 (23 λ, 5 κ) 10 3
Free light chain
antibodies n=41
21 λ+ve, 2 λ −ve, 4 κ+ve, 1
κ & AA+ve (25/28 (89%)
unambiguously diagnostic)
9 −ve, 1 κ
& AA+ve
3 −ve
Conventional light
chain antibodies
n=32
14 λ+ve, 5 λ −ve, 1 κ+ve, 2
κ –ve (15/22 (68%)
diagnostic)
7 −ve 3 −ve
For AL amyloid, difference in proportion unambiguously diagnostic (antibodies to free
light chains – conventional antibodies to light chains)=21% (95% CI 2% to 39%).
Figure 4 The same renal biopsy as in ﬁgure 1. Immunostaining with
the sheep antibody to free λ light chains shows no staining.
Figure 3 The same renal biopsy as in ﬁgure 1. Immunostaining with
the sheep antibody to free κ light chains shows selective staining of
amyloid deposits in glomeruli.
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discordant case, there was a κ paraprotein and a few casts
showed anomalous colours with Congo red as found in some
cases of cast nephropathy, without deﬁnite preponderance of κ
on immunostaining.
Light chain deposition disease
Findings were concordant in all six cases of deposition disease
(ﬁve κ, one λ), with glomerular deposition of the appropriate
light chain, and often deposition in tubular basement mem-
branes (ﬁgure 7).
Other renal effects of immunoglobulin abnormalities
In four of 11 cases, free light chain immunostaining did not
show a preponderance of one light chain. Two were kidneys
inﬁltrated by myeloma and lymphoplasmacytic lymphoma, and
two were cases of cryoglobulinaemia (one type II, one type III).
There was concordance in the other seven cases, all κ, four
cryoglobulinaemic glomerulonephritis (one type I, three type II)
(ﬁgure 8), two tubulointerstitial nephritis with light chains in
tubular basement membranes, and one with crystalline deposits
of light chains in podocytes.
No evidence of renal effects of an immunoglobulin abnormality
In 31 cases, there was no detectable effect of a paraprotein in
the kidney and no immunohistological disproportion between κ
and λ. The commonest diagnoses were diabetic glomerulopathy
(6), membranous nephropathy (4) and chronic ischaemic
damage (4).
Table 3 Summary of immunohistological findings with antibodies to free light chains in 185 renal biopsies and immunoglobulin status of patients (as defined in materials
and methods)
Light chain deposition and
immunoglobulin
abnormality
No light chain deposition and
no immunoglobulin
abnormality
No light chain deposition
and immunoglobulin
abnormality
Light chain deposition and
no immunoglobulin
abnormality
Amyloid n=41 26 (1*) 11 3 (1†, 2*) 1*
Light chain cast nephropathy
n=33
32 – 1* –
Light chain deposition disease
n=6
6 – 0 –
Cryoglobulinaemia n=6 4 – 2 (1†, 1*) –
Miscellaneous n=3 3 – 0 –
Neoplastic infiltration n=2 0 – 2† –
No evidence of renal effects of
immunoglobulin abnormality
n=31
0 – 31† –
No immunoglobulin abnormality
(excluding amyloid cases) n=63
– 62 – 1*
*Considered discordant.
†Not considered discordant, as discussed in text.
Figure 5 Renal biopsy showing light chain cast nephropathy in a
patient with an IgA λ paraprotein. Immunostaining with the sheep
antibody to free λ light chains shows deposition in casts.
Figure 6 The same renal biopsy as in ﬁgure 5. Immunostaining with
the sheep antibody to free κ light chains shows less deposition of κ
than λ (ﬁgure 5).
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No immunoglobulin abnormality
Excluding 12 amyloid cases, 63 biopsies were from patients
without an immunoglobulin abnormality as deﬁned above,
although many had immunoglobulin deposits, shown by anti-
bodies to heavy chains. In 62 there was no disproportion
between κ and λ on immunohistology. One showed subendothe-
lial membranoproliferative glomerulonephritis with more κ than
λ in glomerular deposits, without evidence of a monoclonal
gammopathy.
DISCUSSION
Immunoﬂuorescence on frozen sections and immunoperoxidase
or immunoﬂuorescence on parafﬁn sections rarely show com-
plete concordance in detection of light chain deposition. Which
method gives the correct or more clinically relevant ﬁnding is
undetermined.6–9 The discrepancies in our study were minor
and of uncertain clinical signiﬁcance.
Comparison on parafﬁn sections between free light chain
and conventional antibodies showed that differences were due
to the antibodies, not pretreatments. The free light chain anti-
bodies did not detect whole immunoglobulins and were more
sensitive than conventional antibodies (table 1). Light chains
in deposits were readily differentiated from background. The
free light chain antibodies were better at typing AL amyloid,
giving stronger and generally unequivocal staining (ﬁgures 3,
4; table 2). Two of 28 cases (7%) of AL amyloid were missed,
although to different extents all antibodies to light chains
miss cases of AL amyloid, up to 35% in one series.14 16 17
Some cases of AL amyloid will still need other investigations
for deﬁnitive diagnosis, such as laser microdissection of sec-
tions and mass spectrometry.17 18 Reactivity of amyloid with
multiple antibodies has been reported, for instance in 34% of
biopsies with AA amyloid,19 and two of our 41 amyloid cases
(5%) showed ambiguous immunostaining for both free κ and
amyloid A. Four amyloid cases (10%) therefore showed
discordance between clinical and immunohistological ﬁndings,
overlooking one case with a paraprotein but conﬁrmed to be
AA amyloid.
The free light chain antibodies were useful in conﬁrmation
of deposition disease, with complete concordance, and usually
of cryoglobulinaemic glomerulonephritis (ﬁgures 7, 8). The dis-
cordant case of type II cryoglobulinaemia, with mixed mono-
clonal IgM and polyclonal IgG, may have had insufﬁcient
excess of free light chains to be detectable. In type III cryoglo-
bulinaemia, with polyclonal deposits, no excess of one free
light chain would be expected, and was not considered dis-
cordant. There was little difference between free light chain
and conventional antibodies in detection of light chains in cast
nephropathy. The failure of free light chain antibodies to show
an excess of one light chain in one of 33 cases (3%) may be
because in virtually every case of cast nephropathy both light
chains are found (ﬁgures 5, 6), and a small excess of one may
be undetectable.
The free light chain method was developed to detect depos-
its rather than intracellular or surface immunoglobulins, and
neoplastic inﬁltrates can be investigated in other ways.20 There
was no deposition of free light chains in 32 cases with a mono-
clonal gammopathy but without diagnosable renal effects,
including one case of AA amyloid (29% of those with
immunoglobulin abnormalities). Similarly, 27% of patients with
myeloma3 and 63% with a monoclonal gammopathy1 had no
evidence of renal lesions related to a paraprotein. Accordingly,
only seven of 185 cases (4%) were considered discordant: four
amyloid, one cryoglobulinaemia, one light chain cast nephropa-
thy, and one glomerulonephritis with excess κ deposition but
no gammopathy.
Polyclonal free light chain antibodies are of practical use in
the study of renal biopsies and have advantages over conven-
tional light chain antibodies. Methods are similar and overall
costs are also likely to be similar.
Figure 7 Renal biopsy showing light chain deposition disease in a
patient with a κ paraprotein. Immunostaining with the sheep antibody
to free κ light chains shows deposition in mesangium and tubular
basement membranes. There was no deposition of free λ light chains.
Figure 8 Renal biopsy showing type II cryoglobulinaemic
glomerulonephritis in a patient with an IgM κ paraprotein.
Immunostaining with the sheep antibody to free κ light chains shows
extensive deposition in glomeruli. There was no deposition of free λ
light chains.
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Take home messages
▸ Polyclonal antibodies to free light chains are an
improvement on conventional antibodies to light chains in
the immunoperoxidase study of parafﬁn sections of renal
biopsy specimens, giving a cleaner background and sharper
discrimination of sites of deposition.
▸ These antibodies are more sensitive than conventional
antibodies in the detection of cases of immunological disorders
in the kidney such as AL amyloid, light chain deposition
disease and cryoglobulinaemic glomerulonephritis.
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